CMTM6 maintains the expression of PD-L1 and regulates anti-Tumour immunity

Nature

Volumn 549, Issue 7670, 2017, Pages 101-105

  Burr, Marian L ^a,b,c   Sparbier, Christina E ^a   Chan, Yih Chih ^a   Williamson, James C ^c   Woods, Katherine ^d,e   Beavis, Paul A ^a,b   Lam, Enid Y N ^a,b   Henderson, Melissa A ^a,b   Bell, Charles C ^a,b   Stolzenburg, Sabine ^a   Gilan, Omer ^a,b   Bloor, Stuart ^c   Noori, Tahereh ^a   Morgens, David W ^f   Bassik, Michael C ^f   Neeson, Paul J ^a,b   Behren, Andreas ^d,e   Darcy, Phillip K ^a,b   Dawson, Sarah Jane ^a,b   Voskoboinik, Ilia ^a,b   Trapani, Joseph A ^a,b   Cebon, Jonathan ^d,e   Lehner, Paul J ^c   Dawson, Mark A ^a,b   more..

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d LA TROBE UNIVERSITY   (Australia)

^e OLIVIA NEWTON JOHN CANCER RESEARCH INSTITUTE   (Australia)

^f STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; PROTEIN; PROTEIN CMTM6; UNCLASSIFIED DRUG; CD274 PROTEIN, HUMAN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN; PROTEOME;

APOPTOSIS; CANCER; CELLS AND CELL COMPONENTS; GENE EXPRESSION; IMMUNITY; PROTEIN; PROTEOMICS; TUMOR;

ARTICLE; CANCER CELL; CASE REPORT; CELL MATURATION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; CRISPR-CAS9 SYSTEM; ENDOSOME; HUMAN; HUMAN CELL; IMMUNE EVASION; IN VITRO STUDY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; NEOPLASM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; QUANTITATIVE ANALYSIS; T LYMPHOCYTE; TUMOR IMMUNITY; ANIMAL; BIOSYNTHESIS; CELL LINE; CELL MEMBRANE; CRISPR CAS SYSTEM; ENZYME SPECIFICITY; FEMALE; IMMUNOLOGY; LYSOSOME; METABOLISM; MOUSE; TUMOR ESCAPE;

ANIMALS; B7-H1 ANTIGEN; CELL LINE; CELL MEMBRANE; CRISPR-CAS SYSTEMS; ENDOSOMES; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; LYSOSOMES; MEMBRANE PROTEINS; MICE; NEOPLASMS; PROTEOLYSIS; PROTEOME; SUBSTRATE SPECIFICITY; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 85029029250     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature23643     Document Type: Article

References (19)

1. Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56-61 (2015).
2. Boussiotis, V. A. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N. Engl. J. Med. 375, 1767-1778 (2016).
3. Green, M. R. et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116, 3268-3277 (2010).
4. Kataoka, K. et al. Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers. Nature 534, 402-406 (2016).
5. Morgens, D. W. et al. Genome-scale measurement of off-Target activity using Cas9 toxicity in high-Throughput screens. Nat. Commun. 8, 15178 (2017).
6. Han, W. et al. Identification of eight genes encoding chemokine-like factor superfamily members 1-8 (CKLFSF1-8) by in silico cloning and experimental validation. Genomics 81, 609-617 (2003).
7. Sánchez-Pulido, L., Martín-Belmonte, F., Valencia, A. & Alonso, M. A. MARVEL: A conserved domain involved in membrane apposition events. Trends Biochem. Sci. 27, 599-601 (2002).
8. Weekes, M. P. et al. Latency-Associated degradation of the MRP1 drug transporter during latent human cytomegalovirus infection. Science 340, 199-202 (2013).
9. Matheson, N. J. et al. Cell surface proteomic map of HIV infection reveals antagonism of amino acid metabolism by Vpu and Nef. Cell Host Microbe 18, 409-423 (2015).
10. Grant, B. D. & Donaldson, J. G. Pathways and mechanisms of endocytic recycling. Nat. Rev. Mol. Cell Biol. 10, 597-608 (2009).
11. van Weert, A. W., Geuze, H. J., Groothuis, B. & Stoorvogel, W. Primaquine interferes with membrane recycling from endosomes to the plasma membrane through a direct interaction with endosomes which does not involve neutralisation of endosomal pH nor osmotic swelling of endosomes. Eur. J. Cell Biol. 79, 394-399 (2000).
12. Arjonen, A., Alanko, J., Veltel, S. & Ivaska, J. Distinct recycling of active and inactive β 1 integrins. Traffic 13, 610-625 (2012).
13. Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571 (2014).
14. Homet Moreno, B., Parisi, G., Robert, L. & Ribas, A. Anti-PD-1 therapy in melanoma. Semin. Oncol. 42, 466-473 (2015).
15. Li, C. W. et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat. Commun. 7, 12632 (2016).
16. Behren, A. et al. The Ludwig institute for cancer research Melbourne melanoma cell line panel. Pigment Cell Melanoma Res. 26, 597-600 (2013).
17. Woods, K. & Cebon, J. Tumor-specific T-cell help is associated with improved survival in melanoma. Clin. Cancer Res. 19, 4021-4023 (2013).
18. Boutros, C. et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat. Rev. Clin. Oncol. 13, 473-486 (2016).
19. Mahoney, K. M., Rennert, P. D. & Freeman, G. J. Combination cancer immunotherapy and new immunomodulatory targets. Nat. Rev. Drug Discov. 14, 561-584 (2015)